Antibodies Archives

News and Trends 15 May 2018

Series B Funding Helps Dutch Biotech Fight Graft Versus Host Disease

Xenikos has raised $30M (€25M) in Series B funding to conduct Phase III trials for its treatment for acute graft-versus-host disease, a complication of stem cell transplants. Xenikos has raised a substantial Series B fundraising round to conduct Phase III trials in the US and the EU for T-Guard, its treatment for steroid-resistant acute graft […]

May 15, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 9 May 2018

Swiss Spin-off Secures Funding for Antibodies to Reach Difficult Targets

Memo Therapeutics has raised CHF 5M (€4,2M) to develop its antibody detection technology, which uses whole antibodies to reach difficult targets. Memo Therapeutics, a spin-off from ETH Zurich, has closed a Series A2 round of CHF 5M (€4,2M). The funding was provided by Redalpine Venture Partners and Zurich Cantonal Bank among other investors and will […]

May 9, 2018 - 1 minutemin - By Alexander Burik

News and Trends 20 Feb 2018

Morphosys and Galapagos Announce Positive Phase I Results for Atopic Dermatitis Treatment

Phase I results show promise for a new treatment for atopic dermatitis that may become a strong competitor to the market leader, Humira. Morphosys and Galapagos are developing an antibody that could compete with the world’s best selling drug, Humira. The team announced details on positive results of a Phase I trial for treating atopic dermatitis […]

February 20, 2018 - 3 minutesmins - By Alexander Burik

Interview 12 Feb 2018

MorphoSys’ CEO Tells Us What’s Next for Europe’s Antibody Expert

After 25 years, MorphoSys finally got over the line in 2017 with the FDA approval of its first antibody. CEO Simon Moroney tells us how the company hopes to build on its recent success. It may have started out as a tech provider, but MorphoSys now stands as one of the leading German biotechs, specializing […]

February 12, 2018 - 8 minutesmins - By Alex Dale

News and Trends 30 Jan 2018

Two Biotechs Team Up to Test their Cancer Antibody Combo in the Clinic

Innate Pharma and MedImmune will test the combination of Innate’s cancer antibody and the checkpoint inhibitor durvalumab in patients with solid tumors. Innate Pharma uses antibodies to enhance the immune system’s ability to fight cancer. It has formed a clinical trial collaboration with the MedImmune, an R&D arm of AstraZeneca. The two companies will share the costs […]

January 30, 2018 - 3 minutesmins - By Alex Dale

News and Trends 22 Jan 2018

Novartis Takes Genmab’s Leukemia Drug Off the Market

Genmab’s leukemia drug will be available around the world through compassionate use programs, while it will continue to be marketed as normal in the US. Blockbuster drug owner Genmab developed Arzerra for the treatment of chronic lymphocytic leukemia (CLL) but the drug will be taken off the market outside the US due to its low uptake. Novartis markets the drug and […]

January 22, 2018 - 3 minutesmins - By Alex Dale

News and Trends 22 Jan 2018

Abcam Will Start Selling Over 700 Antibodies from Roche

Abcam and Roche have entered an agreement that will let Abcam sell 760 new antibodies to researchers worldwide through its online platform. Inspired by Amazon, Abcam has become one of Europe’s biggest biotechs by building a platform to make it easier for researchers to order the antibodies they need for their experiments. A new deal with […]

January 22, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Jan 2018

Swedish Biotech Pockets $6M as its Cancer Antibody Heads for the Clinic

Alligator Bioscience will receive milestone payments from its partner, Janssen, following the announcement of a combination trial using its cancer antibody. Alligator develops antibodies to fight cancer, and today it has announced that it will receive $6M (€5M) in milestone payments from Janssen. This was triggered by the announcement of a combination trial for its candidate, ADC-1013, which […]

January 4, 2018 - 2 minutesmins - By Alex Dale

News and Trends 14 Dec 2017

Belgian Biotech Raises $231M to Continue Developing its Antibody Therapies

Argenx has smashed its target of $150M for its US offering, which will support its cancer and autoimmune disease antibodies through the clinic. Argenx develops antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Today, the Belgian biotech has announced that it has raised a very impressive $231M (€195M) following positive results at ASH. The company […]

December 14, 2017 - 1 minutemin - By Alex Dale

News and Trends 11 Dec 2017

Belgian Antibody Proves Effective to Treat Myasthenia Gravis

A Phase II proof of concept study has shown that one of Argenx’ antibodies is effective in treating the neuromuscular disease myasthenia gravis. Argenx has released the results from a Phase II trial with ARGX-113 (efgartigimod), in which the antibody therapy has proved to provide a significant improvement in patients with generalized myasthenia gravis, a form of the disease […]

December 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández

antibiotic antibody staphylococcus symphogen 1

More News! 30 Nov 2017

Cha-Ching! Danish Biotech Gets $5M as Antibody-Antibiotic Combo Enters Phase Ib

A Phase Ib trial will assess the capacity of Symphogen’s antibody to direct an antibiotic to Staphylococcus infections for their effective treatment. Symphogen focuses on the development of antibodies for the treatment of cancer, but will receive a $5M (€4.2M) milestone payment from Genentech for the use of one of its antibodies against Staphylococcus aureus infections. It […]

November 30, 2017 - 2 minutesmins - By Alex Dale

Interview 16 Nov 2017

Waking Up the Immune System with Luc Dochez, CEO of Tusk Therapeutics

Tusk Therapeutics is developing antibodies to ignite the immune system response against cancer. We spoke with CEO Luc Dochez about Tusk and the oncology field. Tusk Therapeutics, based just north of London, focuses on therapeutic antibodies to boost the immune system in the fight against cancer. The company has been developing a number of candidates […]

November 16, 2017 - 6 minutesmins - By Alex Dale

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us